A new PET ligand uncovers brain areas that are teeming with HDACs and other regions devoid of these enzymes.
Clinical trial design could benefit from new estimates of how slowly amyloid accumulates and how best to detect it at various disease stages.
While the relationship between Alzheimer’s and cardiovascular problems such as hypertension and diabetes remains complicated, a history of stroke is said to double the risk of late-onset AD.
In a validation study, three common software packages produced excessive false positives, but initial stories about previous suspect data might have been overblown.
BACE inhibitors are shaping up; pyroglutamate Aβ antibody clears plaques without ARIA, but immune reaction raises a flag.
Scientists report a way to stop transcription of the repeat expansion, leaving the normal gene alone.
Researchers at AAIC discussed technical limitations of current tracers and ways to improve the signal. A new ligand debuted that may be more specific for tangles.
Researchers at AAIC presented congruent data on the place tau tangles take in AD progression, and their close correlation with cognitive decline.
Profile matches Braak staging regions, suggesting those areas are particularly susceptible to AD pathology.
Sequencing the protein-coding DNA regions of more than 60,000 people sheds light on disease-causing mutations.
As data pours in, DIAN leaders strive to share and publish it without accidentally disclosing mutation status. The more is learned about preclinical AD, the harder this may get.
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
At AAIC, updated imaging data in autosomal-dominant AD shows that longitudinal MRI in large numbers of people confirms atrophy patterns. Tau PET is more variable in DIAN participants than in the Colombian families.
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.